Ardelyx, Inc.
(NASDAQ : ARDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.63%62.610.0%$958.21m
NVAXNovavax, Inc. -2.02%94.36251.8%$764.51m
AMGNAmgen, Inc. -1.04%249.041.3%$693.79m
REGNRegeneron Pharmaceuticals, Inc. -3.09%620.862.5%$663.02m
GILDGilead Sciences, Inc. 2.16%76.321.0%$630.80m
BIIBBiogen, Inc. 0.07%278.881.6%$601.57m
VRTXVertex Pharmaceuticals, Inc. -0.32%294.451.9%$475.52m
ILMNIllumina, Inc. -0.63%370.253.5%$301.18m
VXRTVaxart, Inc. -2.56%7.980.0%$286.91m
ALXNAlexion Pharmaceuticals, Inc. 0.32%108.822.0%$217.19m
BMRNBioMarin Pharmaceutical, Inc. -0.59%126.064.3%$206.81m
SRNESorrento Therapeutics, Inc. 4.00%8.061.8%$192.86m
SGENSeattle Genetics, Inc. -3.76%174.356.1%$192.39m
IMMUImmunomedics, Inc. -2.32%41.3211.0%$177.00m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%162.258.5%$166.65m

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.